Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

Hepatocellular carcinoma or HCC is the most commonly observed form of liver cancer and the fourth leading cause of ...

Egypt: Curative liver resection (LR) can be safely carried out in carefully selected elderly patients with hepatocellular ...

A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with ...

In this cohort study involving noncirrhotic patients with chronic hepatitis B, a new prognostic model based on viral load was ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Progression-free survival (PFS) in ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...

Patients with intermediate-stage liver cancer may benefit from receiving a Lenvima-Keytruda combination with transarterial ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...

Foscenvivint is under clinical development by Eisai and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase ...